Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery - PubMed (original) (raw)

. 2002 Aug 27;59(4):514-23.

doi: 10.1212/wnl.59.4.514.

Affiliations

• PMID: 12196642
• DOI: 10.1212/wnl.59.4.514

Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery

Y Li et al. Neurology. 2002.

Abstract

Objective: To test the effect of i.v.-injected human bone marrow stromal cells (hMSC) on neurologic functional deficits after stroke in rats.

Methods: Rats were subjected to transient middle cerebral artery occlusion and IV injected with 3 x 10(6) hMSC 1 day after stroke. Functional outcome was measured before and 1, 7, and 14 days after stroke. Mixed lymphocyte reaction and the development of cytotoxic T lymphocytes measured the immune rejection of hMSC. A monoclonal antibody specific to human cellular nuclei (mAb1281) was used to identify hMSC and to measure neural phenotype. ELISA analyzed neurotrophin levels in cerebral tissue from hMSC-treated or nontreated rats. Bromodeoxyuridine injections were used to identify newly formed cells.

Results: Significant recovery of function was found in rats treated with hMSC at 14 days compared with control rats with ischemia. Few (1 to 5%) hMSC expressed proteins phenotypic of brain parenchymal cells. Brain-derived neurotrophic factor and nerve growth factor significantly increased, and apoptotic cells significantly decreased in the ischemic boundary zone; significantly more bromodeoxyuridine-reactive cells were detected in the subventricular zone of the ischemic hemisphere of rats treated with hMSC. hMSC induced proliferation of lymphocytes without the induction of cytotoxic T lymphocytes.

Conclusion: Neurologic benefit resulting from hMSC treatment of stroke in rats may derive from the increase of growth factors in the ischemic tissue, the reduction of apoptosis in the penumbral zone of the lesion, and the proliferation of endogenous cells in the subventricular zone.

PubMed Disclaimer

Comment in

• Using bone marrow stromal cells for treatment of stroke.
  Rempe DA, Kent TA. Rempe DA, et al. Neurology. 2002 Aug 27;59(4):486-7. doi: 10.1212/wnl.59.4.486. Neurology. 2002. PMID: 12196638 No abstract available.

Similar articles

• Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat.
  Chen J, Li Y, Katakowski M, Chen X, Wang L, Lu D, Lu M, Gautam SC, Chopp M. Chen J, et al. J Neurosci Res. 2003 Sep 15;73(6):778-86. doi: 10.1002/jnr.10691. J Neurosci Res. 2003. PMID: 12949903
• Expression of insulin-like growth factor 1 and receptor in ischemic rats treated with human marrow stromal cells.
  Zhang J, Li Y, Chen J, Yang M, Katakowski M, Lu M, Chopp M. Zhang J, et al. Brain Res. 2004 Dec 24;1030(1):19-27. doi: 10.1016/j.brainres.2004.09.061. Brain Res. 2004. PMID: 15567334
• Allogeneic bone marrow stromal cells promote glial-axonal remodeling without immunologic sensitization after stroke in rats.
  Li Y, McIntosh K, Chen J, Zhang C, Gao Q, Borneman J, Raginski K, Mitchell J, Shen L, Zhang J, Lu D, Chopp M. Li Y, et al. Exp Neurol. 2006 Apr;198(2):313-25. doi: 10.1016/j.expneurol.2005.11.029. Epub 2006 Feb 7. Exp Neurol. 2006. PMID: 16455080
• Treatment of neural injury with marrow stromal cells.
  Chopp M, Li Y. Chopp M, et al. Lancet Neurol. 2002 Jun;1(2):92-100. doi: 10.1016/s1474-4422(02)00040-6. Lancet Neurol. 2002. PMID: 12849513 Review.
• The therapeutic effects of cellular therapy for functional recovery after brain injury.
  Harvey RL, Chopp M. Harvey RL, et al. Phys Med Rehabil Clin N Am. 2003 Feb;14(1 Suppl):S143-51. doi: 10.1016/s1047-9651(02)00058-x. Phys Med Rehabil Clin N Am. 2003. PMID: 12625644 Review.

Cited by

• Narrative review of stem cell therapy for ischemic brain injury.
  Ji XL, Ma L, Zhou WH, Xiong M. Ji XL, et al. Transl Pediatr. 2021 Feb;10(2):435-445. doi: 10.21037/tp-20-262. Transl Pediatr. 2021. PMID: 33708530 Free PMC article. Review.
• Mesenchymal stem cells as a multimodal treatment for nervous system diseases.
  Badyra B, Sułkowski M, Milczarek O, Majka M. Badyra B, et al. Stem Cells Transl Med. 2020 Oct;9(10):1174-1189. doi: 10.1002/sctm.19-0430. Epub 2020 Jun 23. Stem Cells Transl Med. 2020. PMID: 32573961 Free PMC article. Review.
• Differential Migration of Mesenchymal Stem Cells to Ischemic Regions after Middle Cerebral Artery Occlusion in Rats.
  Lee SH, Jin KS, Bang OY, Kim BJ, Park SJ, Lee NH, Yoo KH, Koo HH, Sung KW. Lee SH, et al. PLoS One. 2015 Aug 4;10(8):e0134920. doi: 10.1371/journal.pone.0134920. eCollection 2015. PLoS One. 2015. PMID: 26241653 Free PMC article.
• Protective effects of BDNF overexpression bone marrow stromal cell transplantation in rat models of traumatic brain injury.
  Wang Z, Yao W, Deng Q, Zhang X, Zhang J. Wang Z, et al. J Mol Neurosci. 2013 Feb;49(2):409-16. doi: 10.1007/s12031-012-9908-0. Epub 2012 Nov 11. J Mol Neurosci. 2013. PMID: 23143881
• Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system.
  Laroni A, Novi G, Kerlero de Rosbo N, Uccelli A. Laroni A, et al. J Neuroimmune Pharmacol. 2013 Dec;8(5):1062-76. doi: 10.1007/s11481-013-9456-6. Epub 2013 Apr 12. J Neuroimmune Pharmacol. 2013. PMID: 23579931 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information